Articles tagged with Biomarkers
Researchers at TGen developed a method to isolate protein-rich urinary exosomes, which can help discover biomarkers for better CKD diagnosis and treatment. The study found that the new method produces high yields of miRNA and mRNA, making it suitable for downstream genetic profiling experiments.
Researchers at the University of California, San Diego School of Medicine have identified laboratory-based biomarkers that can help understand brain-based abnormalities in schizophrenia. These endophenotypes could provide clinicians with reliable indicators of brain dysfunction, even when overt symptoms are not apparent.
Research finds that people at risk for early-onset Alzheimer's disease want to know their genetic profile, but struggle with the results. The study also reveals that the general population and those with a family history of late-onset AD tend to be motivated by fear and anxiety when considering genetic testing.
In vitro studies assess propolis' optimal concentration as a radioprotector, finding maximum protection against radiation-induced damage within 120-500 micrograms/mL. The substance does not reveal cytotoxicity or genotoxicity on non-irradiated human lymphocytes.
The study discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles released by tumor cells may provide a unique biosignature for individual cancers, enabling early detection and targeted therapies.
A new study proposes a highly accurate blood-based screen for pancreatic adenocarcinoma, which could lead to earlier detection and improved survival rates. Researchers identified 40 biomarkers with high sensitivity and specificity, offering hope for developing an effective panel.
A new study suggests that Coenzyme Q10 reduces oxidative damage in patients with Huntington's disease, hinting at its potential to slow progression. The discovery also identifies a new biomarker, 80HdG, which could be used to screen experimental treatments for this and other neurological disorders.
Researchers have identified 29 differentially expressed proteins in maternal serum from pregnancies carrying Down syndrome fetuses. These proteins show promise as potential biomarkers for improving the performance of Down syndrome screening, but further clinical verification is needed.
Researchers identified five biomarkers that can predict the progression of structural damage in the spine of patients with Ankylosing Spondylitis, who are already at high risk of disease progression. These biomarkers include matrix metalloproteinase 3, bone-morphogenetic protein 2, and vascular endothelial growth factor.
A study published in JAMA found that certain biomarker levels, specifically troponin T, measured after noncardiac surgery are associated with an increased risk of death within 30 days. The researchers identified peak troponin T values as the strongest predictors of 30-day mortality.
Researchers at Princeton University have developed a new nanotechnology that amplifies fluorescent signals in biological tests, allowing for the detection of biomarkers at lower concentrations. This breakthrough could lead to improved early detection of diseases like cancer and Alzheimer's, enabling more effective treatment.
Researchers at NYU College of Dentistry will screen subjects and collect biological samples to contribute to the overall project on biomarkers of periodontal disease progression. The study aims to identify factors that indicate susceptibility to developing periodontal disease and design more specific treatments.
Researchers suggest enhanced public funding, partnerships, and open-source consortia may improve biomarker discovery and development. The Supreme Court's move to free medical diagnosis from private ownership could enhance public health.
Researchers identified novel biomarkers in rat feces after radiation exposure, which persisted for at least 21 days. These findings hold promise for rapid, accurate diagnosis of radiation exposure, enabling timely resource allocation for patients in need of intervention.
Researchers have identified a biomarker that can predict which patients will benefit from bevacizumab treatment. The variant in DNA found in blood samples of cancer patients showed predictive value for treatment with bevacizumab, potentially allowing for patient-tailored use of the drug and increasing the chances of survival.
SomaLogic and NEC announce the release of SomaSuite, a professional software tool that simplifies the analysis of proteomic data generated by SomaLogic's SOMAscan assay technology. The tool enables researchers to quickly discover significant protein expression changes in their biological samples.
A modified version of Google's PageRank algorithm is used to rank proteins by their genetic relevance to pancreatic cancer progression. Seven proteins were found that can help assess tumor aggressiveness and guide treatment decisions.
Researchers linked air pollution exposure to increased risk of cardiovascular problems, as shown by significant reductions in blood clotting and inflammation biomarkers during the Beijing Olympics. The study provides evidence that even short-term air pollution reduction improves cardiovascular health.
Researchers measured environmental air pollutants and biomarkers for systemic inflammation and thrombosis before, during, and after the 2008 Olympics. Concentrations of particulate and gaseous pollutants decreased substantially, but ozone concentrations increased.
Researchers from SomaLogic and the University of Washington identified 36 proteins with significant expression changes in lung cancer tissue samples, including 13 new biomarkers. This study provides new insights into NSCLC biology and suggests potential therapeutic targets.
A study of 112 patients with Parkinson's disease and 60 controls found that persistent ocular tremors were universally present in patients with PD, regardless of medication use. This finding suggests that precise oculomotor testing could be a valuable tool for early diagnosis.
Researchers found a decrease in cerebrospinal fluid biomarker P-tau following treatment with bapineuzumab, suggesting potential benefits for Alzheimer's patients. However, further examination is needed to determine if these changes correlate with clinical improvements.
Researchers at Uppsala University have identified potential biomarkers for autism spectrum disorder using advanced mass spectrometry. The study found disruptions in the nervous system and a connection between protein C3 and ASD, which may lead to a reliable blood-based diagnostic tool.
Recent studies have increased interest in salivary biomarkers for diagnostics, but challenges persist in collection, storage, and quantitation of biomarkers. Researchers will discuss standardization procedures and address issues with proteomic methods.
A clinical trial examining the antioxidant effects of a vitamin E and C combination on Alzheimer's disease found no association with changes in cerebrospinal fluid biomarkers. However, the treatment was shown to reduce oxidative stress in the brain, but at the cost of faster cognitive decline.
A recent study found that adding inflammatory biomarkers improves the clinical prediction of mortality in patients with chronic obstructive pulmonary disease (COPD). The addition of a panel of selected biomarkers significantly improved the ability of clinical variables to predict mortality, with a C-statistic of 0.726.
Recent advances in biomarker discovery highlight the potential for personalized medicine, but also pose significant challenges. Biomarkers have been identified for various diseases, including idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and systemic lupus erythematosus.
A panel of 10 serum protein biomarkers shows promise in predicting lung cancer risk and aiding early detection. Research suggests that these biomarkers could reduce the number of unnecessary lung biopsies needed, offering a more targeted approach to diagnosis.
The SOMAscan assay identifies and measures thousands of proteins, unlocking protein biomarker discovery for therapeutic and diagnostic applications. This technology empowers personalized medicine by detecting early disease onset in real-time.
Researchers at Arizona State University have identified over 1,200 proteins in umbilical cord blood, providing valuable information for the identification of biomarkers. The findings represent a significant advance in the discovery of early warning indices of disease and toxic exposure.
SomaLogic will develop a low-cost diagnostic tool using its proteomic technology to detect TB biomarkers. The grant aims to improve identification of active TB cases in developing countries.
The Forsyth Institute is developing a low-cost diagnostic tool for tuberculosis (TB), which can quickly and accurately diagnose active TB cases in developing countries. The project focuses on identifying and validating seven proteins of Mycobacterium tuberculosis as biomarkers of active disease.
The University of Louisville will receive a $576,800 grant to develop a low-cost, simple test for diagnosing tuberculosis (TB) in developing countries. Researchers aim to identify and validate TB biomarkers using a disposable sampling plate and breath test.
A short spinning session can increase cardiac biomarkers, similar to a heart attack, but levels return to normal within 24 hours. Researchers hope to raise awareness among emergency treatment teams about the need for accurate assessment in patients with chest pains after exercise.
Henry Ford Hospital researchers have identified two molecules that hold promise as a biomarker for measuring cartilage damage associated with osteoarthritis. Non-coding RNAs in blood were found to be associated with mild cartilage damage in patients one year after ACL reconstruction surgery.
Researchers at Sam Houston State University have discovered a new biomarker, ACTA, in liver samples following cyanide poisoning, which may extend its detection window up to two months. Elevated cyanide concentrations can only be detected for up to two days under current toxicological testing.
A new blood test developed by Ridge Diagnostics analyzes levels of nine biomarkers to accurately diagnose major depressive disorder with a sensitivity of about 90% and specificity of 80%. The test, known as MDDScore, could improve diagnostic accuracy and help track individual patients' response to treatment.
Researchers identified two biomarkers, NGAL and Kim1, that predict poor outcomes in hospitalization and require dialysis treatment. Early detection of acute kidney injury is crucial to devise an adequate treatment strategy for patients.
Researchers identified 56 genes associated with inflammation and lipid metabolism to detect atherosclerosis. The biomarker test uses a blood sample and can predict the risk of silent atherosclerosis in clinical practice.
A new highly sensitive troponin assay has been shown to be superior in diagnosing heart attacks, allowing for earlier and more accurate treatment. The study found that using this test on admission and measuring changes after 3 hours can rule out or confirm a diagnosis of heart attack with high accuracy.
Researchers identified two distinct biomarker patterns that continue to improve with time, even after partial weight regain. These improvements suggest long-term effects of healthier dietary habits on cardiovascular health and organ function.
A new study provides clear procedures for collecting and analyzing microRNAs, significantly improving diagnostic accuracy. Researchers developed measures to overcome interfering activities and improved the sensitivity of miRNA detection by up to 30-fold, enabling faithful quantitation of miRNA abundance in body fluids.
Researchers at MU College of Veterinary Medicine have identified a biomarker that can indicate infection in dogs, which may also be applicable to humans. This breakthrough could lead to the development of a portable bedside test for quick diagnosis and targeted treatment, reducing antibiotic use and promoting better health outcomes.
Scleroderma is a chronic autoimmune disease affecting 300,000 US citizens, causing skin thickening and internal organ damage. Researchers at Northwestern will identify biomarkers using proteomics to develop targeted therapies.
A randomized double-blind clinical trial found that regular consumption of vitamin D-fortified yoghurt drink improved endothelial biomarkers in subjects with type 2 diabetes. Vitamin D levels were also elevated in most patients, leading to reduced cholesterol levels and insulin resistance.
A systematic review of delirium biomarkers found that clinicians are not using these chemical indicators to diagnose or treat patients with delirium. Biomarkers linked to delirium provide a window into the disease process, enabling better recognition and management of the condition.
A new mathematical model developed by Stanford University scientists can help guide attempts to improve blood-based tumor detection methods. The model predicts that tumors can grow for 10 years or longer before detection using current blood tests, but may allow early detection within a shorter timeframe with the right biomarker.
The BBVA Foundation-funded Tumor Biomarkers Research Program aims to develop targeted therapies for various types of cancer, including colorectal, breast, and lung cancer. The program will utilize biomarkers to identify unique molecular characteristics in each patient's tumor.
A Virginia Tech research team has created a microelectromechanical system to detect trace amounts of toxins in breath on the parts per billion scale. The study aims to monitor patient exhaled breath to identify and quantify environmental exposure risks, providing valuable data for limiting harmful contaminant exposure.
The Arizona State University-led initiative aims to identify molecular markers for type 2 diabetes and cardiovascular disease risk, with the goal of predicting heart attack risk and assessing potential new treatments. The project will use proteomics and mass spectrometry technology to discover and validate biomarkers.
Researchers have discovered a panel of proteins shed by breast cancer that can distinguish between real cancer and benign lumps. The biomarker panel outperforms mammograms and single biomarkers in distinguishing between breast cancer and benign lumps, with some panels ranking above 0.95.
Researchers have found a biomarker that can rapidly identify severe graft-versus-host disease of the intestine in hematopoietic cell transplant patients with leukemia, lymphoma or other blood disorders. The biomarker, REG3-alpha, helps doctors ensure patients receive appropriate treatment as early as possible.
Researchers at Brigham and Women's Hospital and Massachusetts General Hospital have identified a transcriptional biomarker that may assist in the monitoring of Huntington's disease activity and the evaluation of new medications. The biomarker, H2AFY, is overexpressed in the blood of individuals with Huntington's disease.
A study aims to utilize Galectin-3 and HBME-1 proteins as biomarkers for thyroid cancer diagnosis, enabling earlier detection and reducing surgical interventions. The research has the potential to improve patient outcomes by accurately identifying patients at risk of cancer.
Researchers at Duke University Medical Center have found a genetic variant associated with lower five-year survival rates after coronary artery bypass graft. The thrombomodulin (THBD) gene was independently linked to increased long-term mortality risk following CABG procedure.
Researchers found high serum BDNF levels among alcohol-dependent individuals, which may predict relapse. Abstinence and non-abstinence conditions showed increased BDNF levels over time, indicating neurological transformations reflected by peripheral BDNF levels.
Researchers discovered a DNA biomarker, GSTP1, in bodily fluids that can complement the PSA test to increase prostate cancer diagnosis accuracy. The new blood test may reduce unnecessary biopsies and provide physicians with reassurance about biopsy recommendations.
Researchers are studying biomarkers in the blood of TBI patients to improve diagnosis and treatment. The study aims to validate biomarkers as predictors of clinical outcome and evaluate the relationship between progesterone treatment and biomarker levels.
Advances in nanotechnology are driving innovation in mass spectrometry instrumentation, enabling faster and more precise biomarker validation. Researchers have developed novel nanoflow separation methodologies that ramp up the speed and precision of validating biomarkers.
The search for biomarkers has made significant strides in disease diagnosis and treatment monitoring, with some tests already incorporated into everyday medicine. However, recent studies have shown that promising cancer biomarkers are no better than existing ones, highlighting the need for new approaches.